SCHEMBL4501207

SCHEMBL4501207

O=C1C(Cc2c(Cl)cccc2Cl)CCCN1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EPHX2 P34913 1/20 0.34
HSD11B1 P28845 5/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
TSHR P16473 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
GLA P06280 1/20 0.31
HTT P42858 1/20 0.31
CYP2A13 Q16696 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519727 0.96 HSD11B1 (0.35) P2RX7ALDH1A1MAPTKMT2ANPSR1
SCHEMBL4507429 0.93 EPHX2 (0.37) P2RX7ALDH1A1MAPTKMT2ANPSR1
SCHEMBL14365292 0.82 HSD11B1 (0.36) EPHX2HSD11B1
SCHEMBL4520440 0.79 IDE (0.35) P2RX7ALDH1A1KMT2ASMN1; SMN2EPHX2
SCHEMBL4514682 0.78 GAA (0.43) P2RX7ALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL4504367 0.77 EPHX2 (0.31) P2RX7ALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL4501748 0.76 LMNA (0.35) P2RX7ALDH1A1MAPTKMT2ANPSR1
SCHEMBL4506472 0.74 ALDH1A1 (0.48) P2RX7ALDH1A1MAPTKMT2AMEN1
SCHEMBL4505135 0.73 P2RX7 (0.36) P2RX7ALDH1A1MAPTKMT2ANPSR1
SCHEMBL13674410 0.73 HSD11B1 (0.56) ALDH1A1KMT2AMEN1SMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 P2RX7 3946/4885ALDH1A1 51/4885MAPT 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.